- Home
- FLYE vs VBIO Comparison
FLYE vs VBIO Comparison
Compare FLYE & VBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
SELL
Current Price
$2.10
HOLD
Current Price
$1.68
Company Overview
Basic Information| Metric | FLYE | VBIO |
|---|---|---|
| Founded | 2018 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Aerospace | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.3M | 2.0M |
| IPO Year | 2024 | 2021 |
Fundamental Metrics
Financial Performance| Metric | FLYE | VBIO |
|---|---|---|
| Price | $2.10 | $1.68 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 3.2M | 711.0K |
| Earning Date | 09-01-2026 | 11-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 61.82 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $19,063,357.00 | $780,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.22 | $0.12 |
| 52 Week High | $109.00 | $812.50 |
Technical Indicators
Market Signals| Indicator | FLYE | VBIO |
|---|---|---|
| Relative Strength Index (RSI) | 62.21 | 23.18 |
| Support Level | $1.53 | $0.12 |
| Resistance Level | $2.29 | $4.39 |
| Average True Range (ATR) | 0.27 | 0.49 |
| MACD | 0.11 | 3.74 |
| Stochastic Oscillator | 40.44 | 1.79 |
Price Performance
Historical Comparison FLYE
VBIO
About FLYE Fly-E Group Inc.
Fly-E Group Inc is principally engaged in designing, installing and selling smart electric motorcycles, electric bikes, electric scooters, and related accessories under the Fly E-Bike brand. It offers 27 E-motorcycle products, 37 E-bike products and 38 E-scooter products.
About VBIO Valion Bio Inc. Common Stock
Valion Bio Inc is a late-stage biopharmaceutical company developing biologics that activate innate immune pathways for cytoprotection and immune modulation. Its main candidate, Entolimod, is a TLR5 agonist and also advances Entolasta, a next-generation TLR5 agonist, and targets the neutropenia oncology supportive care market.